Drug Type AAV based gene therapy |
Synonyms- |
Target |
Action modulators |
Mechanism GUCY2D modulators(guanylate cyclase 2D, retinal modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Retinal Dystrophies | Preclinical | United States | 11 Feb 2026 | |
| Retinal Diseases | Preclinical | United States | 19 Oct 2021 |





